CA2259194A1 - Transdermal compositions containing levosimendan - Google Patents

Transdermal compositions containing levosimendan

Info

Publication number
CA2259194A1
CA2259194A1 CA002259194A CA2259194A CA2259194A1 CA 2259194 A1 CA2259194 A1 CA 2259194A1 CA 002259194 A CA002259194 A CA 002259194A CA 2259194 A CA2259194 A CA 2259194A CA 2259194 A1 CA2259194 A1 CA 2259194A1
Authority
CA
Canada
Prior art keywords
levosimendan
compositions containing
transdermal compositions
transdermal
containing levosimendan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002259194A
Other languages
French (fr)
Other versions
CA2259194C (en
Inventor
Arto Urtti
Jouni Hirvonen
Lasse Lehtonen
Saila Antila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Corporation
Arto Urtti
Jouni Hirvonen
Lasse Lehtonen
Saila Antila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614098.3A external-priority patent/GB9614098D0/en
Application filed by Orion Corporation, Arto Urtti, Jouni Hirvonen, Lasse Lehtonen, Saila Antila filed Critical Orion Corporation
Publication of CA2259194A1 publication Critical patent/CA2259194A1/en
Application granted granted Critical
Publication of CA2259194C publication Critical patent/CA2259194C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Abstract

Transdermal administration of levosimendan or (-)-[[4-(1,4,5,6-tetrahydro-4methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile or a pharmaceutically acceptable salt thereof is disclosed. Transdermal preparations of levosimendan can be in the form of e.g. ointment, emulsion, lotion, solution, gel, cream, patch or transdermal delivery device including iontophoretic device.
CA002259194A 1996-07-05 1997-06-26 Transdermal compositions containing levosimendan Expired - Fee Related CA2259194C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9614098.3 1996-07-05
GBGB9614098.3A GB9614098D0 (en) 1996-07-05 1996-07-05 Transdermal delivery of levosimendan
PCT/FI1997/000412 WO1998001111A1 (en) 1996-07-05 1997-06-26 Transdermal compositions containing levosimendan

Publications (2)

Publication Number Publication Date
CA2259194A1 true CA2259194A1 (en) 1998-01-15
CA2259194C CA2259194C (en) 2007-06-19

Family

ID=38282788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002259194A Expired - Fee Related CA2259194C (en) 1996-07-05 1997-06-26 Transdermal compositions containing levosimendan

Country Status (1)

Country Link
CA (1) CA2259194C (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514477A1 (en) * 2011-04-19 2012-10-24 Palo Alto Research Center Incorporated Delivery devices with collimated gas stream and particle source
JP2012223560A (en) * 2011-04-19 2012-11-15 Palo Alto Research Center Inc Drug delivery device and method with collimated gas stream and release-activatable tape
US8430839B2 (en) 2011-04-19 2013-04-30 Palo Alto Research Center Incorporated Drug delivery devices and methods with collimated gas stream and drug reservoir

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2514477A1 (en) * 2011-04-19 2012-10-24 Palo Alto Research Center Incorporated Delivery devices with collimated gas stream and particle source
JP2012223560A (en) * 2011-04-19 2012-11-15 Palo Alto Research Center Inc Drug delivery device and method with collimated gas stream and release-activatable tape
US8388569B2 (en) 2011-04-19 2013-03-05 Xerox Corporation Delivery devices and methods with collimated gas stream and particle source
US8430839B2 (en) 2011-04-19 2013-04-30 Palo Alto Research Center Incorporated Drug delivery devices and methods with collimated gas stream and drug reservoir
US8486002B2 (en) 2011-04-19 2013-07-16 Palo Alto Research Center Incorporated Drug delivery devices and methods with collimated gas stream and release-activatable tape

Also Published As

Publication number Publication date
CA2259194C (en) 2007-06-19

Similar Documents

Publication Publication Date Title
GR3037083T3 (en) Transdermal compositions containing levosimendan
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
AU6029096A (en) Compositions and methods for topical administration of pharm aceutically active agents
CA2245142A1 (en) New phenanthridines
CA2274074A1 (en) Novel compounds with analgesic effect
CA2098302A1 (en) Medicaments
CA2203033A1 (en) Compounds and compositions for delivering active agents
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
WO2000007979A3 (en) Compounds and compositions for delivering active agents
CA2169087A1 (en) Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
FR2784294B1 (en) COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING AT LEAST ONE WALL EXTRACT, AT LEAST ONE SCUTELLAR EXTRACT AND AT LEAST ONE SALICYLIC ACID DERIVATIVE
GEP20012442B (en) Irreversible Inhibitors of Tyrosine Kinases
WO1994001407A3 (en) Indole and indene derivatives as pla2 and lipoxygenase inhibitors
IE790756L (en) Cerebral therapeutic agent
CA2254079A1 (en) Androstene derivatives
NO952906L (en) Pharmaceutical formulation for the treatment of nicotine addiction
EP0158481A3 (en) Hair care compositions
CA2134972A1 (en) Anti-ischemic medicament
CA2271944A1 (en) Formulation for electrically assisted delivery of lidocaine and epinephrine
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
CA2259194A1 (en) Transdermal compositions containing levosimendan
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EP0842663A4 (en) Ophthalmic preparations
CA2285985A1 (en) A method for preparing aqueous liposomal compositions comprising an active ingredient which is highly insoluble in water

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed